Jan Zamek

Jan Zamek

Auto-generated profile, based on publicly available information

Jan Zamek

Department of Dermatology and Venereology, University of Cologne, Faculty of Medicine, and University Hospital of Cologne, Cologne, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MKMaike Kümper
Maike Kümper
SHSabrina Hessenthaler
Sabrina Hessenthaler
JZJan Zamek
Jan Zamek
SNStephan Niland
Stephan Niland
EPElke Pach
Elke Pach
Paola ZigrinoPaola Zigrino
Paola Zigrino

29 May 2026 in Science Advances
Verified
Journal Article
Open access
MAManuel Huerta Arana
Manuel Huerta Arana
HKHenning Klapproth
Henning Klapproth
MSMichal A. Stanczak
Michal A. Stanczak
LBLuisa Bopp
Luisa Bopp
KWKarla Witschurke
Karla Witschurke
MFMario Fabri
Mario Fabri
Granuloma annulare (GA) and cutaneous sarcoidosis (cSAR) have an overlapping immunopathology, in which the aberrant activation of macrophages by IFN-γ constitutes a central driver. Nevertheless, the molecular understanding in GA and cSAR macrophages remains limited. We reanalyzed single-cell RNA sequencing data of GA and cSAR and performed in vitro experiments with primary human cells showing that oxidative phosphorylation (OXPHOS) is a dominant metabolic pathway in IFN-γ–activated macrophages. Furthermore, we identify an IFN-γ–induced response network in GA and cSAR macrophages, sensitive to electron transport chain (ETC) inhibitors. Guanylate-binding protein 1 (GBP1) was central in controlling IFN-γ–mediated macrophage activation. Meanwhile, inhibition of IFN-γ signaling, ETC complexes, and GBP1 reduced granuloma formation in a human in vitro model. Metformin, a clinically used ETC complex I inhibitor, suppressed IFN-γ activation of macrophages and in vitro granulomas. Together, we suggest that OXPHOS and GBP1 represent druggable targets in granulomatous diseases and that drug repurposing of metformin is a possible strategy.

16 May 2026 in The American Journal of Pathology
Verified
Journal Article
Open access
BBBirgit Bouriette
Birgit Bouriette
LGLuca Gaessler
Luca Gaessler
JZJan Zamek
Jan Zamek
JSJoy Steinkamp
Joy Steinkamp
PHPitter Huesgen
Pitter Huesgen
Paola ZigrinoPaola Zigrino
Paola Zigrino
Connective tissue remodeling is vital for organ development and tissue stability. Matrix metalloproteinases (MMPs), especially MMP14 and MMP13, are important collagenases that break down interstitial collagen in bone and skin. In mice, the loss of MMP14 results in perinatal death and severe skeletal defects, whereas Mmp13 deficiency causes transient bone defects that later resolve. Despite abundant dermal collagen, single knockouts usually do not display defects in skin formation, likely due to compensatory mechanisms. To examine their combined roles, mice lacking both enzymes were generated. These double-knockout mice were viable at birth but rapidly developed severe symptoms resembling Mmp14 deficiency, including growth retardation, wasting, and death within three weeks. Surprisingly, skin structure remained largely normal, aside from early subcutaneous fat loss also observed in Mmp14-deficient mice, indicating that neither enzyme is essential for early dermal remodeling. In contrast, skeletal defects worsened, showing shortened long bones, delayed primary ossification, impaired collagen type I breakdown, and reduced vascular invasion. These findings indicate that MMP13 partly compensates for MMP14 during bone development, while both enzymes are unnecessary for postnatal dermal collagen remodeling. Since MMP mutations are linked to human skeletal dysplasia, fibrosis, and wound-healing issues, these results underscore the distinct roles of MMP14 and MMP13 in collagen turnover and highlight their potential importance in human bone and connective tissue disorders.